STERIS plc, often abbreviated as STE, is a globally renowned company specializing in infection prevention, decontamination, and health science technologies. The company operates by providing sterilization services, microbial reduction solutions, surgical and critical care products, as well as other life sciences support services in more than 100 countries around the globe.
Founded in 1985 and headquartered in Mentor, Ohio, USA, STERIS has grown into an international enterprise, marking a significant footprint in the global health sector. The British-Irish domiciled company is currently listed on the New York Stock Exchange (NYSE) under the ticker symbol ‘STE’.
STERIS functions through three principal segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers infection prevention and surgical solutions, and encompasses businesses such as Medical Devices, Healthcare Specialty Services and Healthcare Products. On the other hand, the Applied Sterilization Technologies segment provides contract sterilization and microbial reduction services to customers from various end markets, including the medical device, pharmaceutical, and food safety industries. The Life Sciences segment offers products and services for pharmaceutical and medical device manufacturers.
Throughout its existence, STERIS’s strategy has always been focused on improving the productivity, quality, safety, and cost-effectiveness of its customers' operations, while enhancing the benefits and outcomes of patients' lives. The company prides itself on providing unique system solutions by integrating several of their innovative products and services.
STERIS is known for its engagement in continuous research and development to foster new technologies, products, and services. The company's portfolio includes consumable products such as detergents, surgical lubricants, skin care products, device reprocessing systems, endoscope reprocessing, washer-disinfectors, and sterilizers.
Recognized as a leading provider of infection prevention and other procedural products and services, STERIS’s mission is "to HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe". This means that STERIS isn’t just about profit, but about making a positive difference for healthcare providers and patients worldwide.
With its constant commitment to the provision of innovative solutions, STERIS Plc has successfully established a strong reputation in the global healthcare sector. Despite the numerous challenges in the global health industry, STERIS has demonstrated resilience, navigated through and emerged as an industry leader, setting the pace for peers and competitors.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article details significant leadership changes in the eyecare industry, including the stepping down of CEOs at LENZ Therapeutics and CooperCompanies. LENZ Therapeutics is undergoing a strategic reorganization, cutting 75% of its workforce, while CooperCompanies' new Executive Chair, Walter Rosebrough, aims to address recent performance issues. Other executive appointments are also highlighted across Carl Zeiss Meditec AG, Tarsus Pharmaceuticals, RxSight, Zenni Optical, Balance Ophthalmics, and Ocuco.
Shares of Steris PLC (STE) fell 2.16% to $227.12 on Friday, contrasting with a broader market decline where the S&P 500 Index and Dow Jones Industrial Average also dropped. This decline ended a two-day winning streak for the stock.
Soltis Investment Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 26.5%, purchasing an additional 35,100 shares to bring its total holdings to 167,746 shares valued at approximately $14.5 million. This acquisition highlights institutional confidence, despite recent insider sales totaling nearly $5.9 million. Medtronic reported strong quarterly earnings, exceeding analyst expectations, and offers a 3.0% annual dividend yield.
Shares of Steris PLC (STE) rose 1.47% to $232.14 on Thursday, outperforming the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average decline. This marks the second consecutive day of gains for the company's stock.
STERIS plc (NYSE:STE) has declared a quarterly dividend of $0.69 per share, maintaining its 20-year streak of dividend increases. The dividend is payable on December 17th to shareholders of record on November 17th, representing an annualized dividend of $2.76 and a yield of 1.2%. The company's dividend payout ratio of 25.1% indicates strong coverage by earnings, with analysts projecting continued coverage based on future EPS estimates.